AMD

Weekly review in ophthalmology: 18 June - 24 June

An end-of-week review of what happened in ophthalmology from 18 June to 24 June.

Is retinal tissue preservation as important as decreased GA expansion in future therapies?

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Dr Karl Csaky and Dr Fredrick Ferris III identified in 2007—Dr Csaky reinforces the importance of preserving the central retinal tissue.

Phase 1 trial finds at-home subcutaneous injection option safe, effective for the treatment of wet AMD, DMO

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.

Gene therapies licensed by Kriya Therapeutics target geographic atrophy, other ocular diseases

February 18, 2022

Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.